U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07144917) titled 'Immunoparalysis After Pancreaticoduodenectomy' on Aug. 20.
Brief Summary: By 2030, pancreatic adenocarcinoma could become the second leading cause of cancer-related death in France. To date, Pancreaticoduodenectomy (PD) is the standard treatment for resectable adenocarcinoma of the pancreatic head. Despite advances in perioperative care, morbidity remains high, and the occurrence of postoperative complications can negatively impact patient's oncologic prognosis.
Sepsis is the leading cause of postoperative death following PD and it remains mainly associated with the development of a clinically-relevant postoperative pancreatic fist...